Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
vision loss
Biotech
J&J hands back failed gene therapy to MeiraGTx
Bota-vec failed a phase 3 trial after J&J shelled out $130 million upfront to fully acquire the gene therapy from MeiraGTx.
Darren Incorvaia
Apr 16, 2026 10:17am
Ocugen’s CEO wants to bring gene therapy to the masses
Apr 16, 2026 9:00am
Fatty acid eye injections restore vision in old mice
Sep 26, 2025 2:10pm
Alcon sees Staar Surgical for $1.5B deal
Aug 5, 2025 11:00am
J&J launches daily contact lens for astigmatism, presbyopia
Jun 23, 2025 11:48am
Atsena gene therapy hits safety goals, closes retinal splits
May 19, 2025 12:59pm